[Newsletter] XENONEWS
November 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...
More[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA
July 11th, 2022. # Download our press information (english version) # Télécharger...
More[Newsletter] XENONEWS
June 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...
More[Press Alert] Safety and efficacy results of LIS1
June 2022. # Download our press information (english version) # Télécharger notre...
More[Press Information] XENOTHERA presents LIS1 results at the American Transplant Congress (ATC) in Boston
May 2022. # Download our press information (english version) # Télécharger notre...
More[ Press Information ] APPOINTMENTS
April 2022. # Download our press information (english version) # Télécharger notre...
More[Newsletter] XENONEWS
February 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...
More[Press information] XENOTHERA announces the continuation of development of its anti-SARS-CoV-2 antibody.
January 2022. # Download our press information (english version) # Télécharger notre...
More[Press Alert] Omicron Variant : positive results for XENOTHERA's XAV-19 antibody
December 2021. # Download our press information (english version) # Télécharger notre...
More[Newsletter] XENONEWS
December 2021. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...
More[ Press Information ]The French biotech XENOTHERA awarded Start-Up of the Year for the Western region.
# Download our press information (english version) # Télécharger notre information presse...
More[Newsletter] XENONEWS
October 2021 >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...
More[Press Release] XENOTHERA signs a memorandum of understanding with the Vietnamese conglomerate Vingroup
September 9,2021. # Download our press release (english version) # Télécharger notre...
More[Press Release] Accelarated Scientific Advise from European Medicines Adgency EMA for XAV19 Market Authorisation
July 8, 2021. # Download our press release (english version) # Télécharger...
More[Newsletter] XENONEWS
Summer 2021. >> Official XENOTHERA newsletter /Lettre d’information officielle de XENOTHERA <<...
More[Press Release] 20 M€ raised by XENOTHERA to accelerate its development
June 29, 2021. # Download our press release (english version) # Télécharger...
More[Press Alert] XENOTHERA signs a pre-order contract of its anti-covid treatment with the French government
May 11, 2021. # Download our press information (english version) # Télécharger...
More[Newsletter] XENONEWS
May 2021 >> Official XENOTHERA newsletter /Lettre d’information officielle de XENOTHERA <<...
More[Press Alert] XENOTHERA And Its Partner Excelya Announce the Recruitment of the First Patient in The EUROXAV Clinical Trial of its COVID Treatment XAV19
May 3, 2021. # Download our press information (english version) # Télécharger...
More[Newsletter] XENONEWS
April 2021 >> Official XENOTHERA newsletter /Lettre d’information officielle de XENOTHERA <<...
More[Press Release] Completion of patients’ enrolment in the POLYCOR clinical trial promoted by the Nantes University Hospital
April 21, 2021. # Download our press release (english version) # Télécharger...
More[Press Release] Effectiveness of XAV19 against SARS-CoV-2 variants
February 1, 2021. # Download our press release (english version) # Télécharger...
More[Newsletter] XENONEWS
March 2021 >> Official XENOTHERA newsletter /Lettre d’information officielle de XENOTHERA <<...
More[Newsletter] XENONEWS
February 2021 >> Official XENOTHERA newsletter /Lettre d’information officielle de XENOTHERA <<...
More